Form 4: ClearPoint Neuro Director Settles Restricted Stock Units
SEC Form 4 Filing
Matthew Klein, a director at ClearPoint Neuro, settled 21,093 restricted stock units into common stock on May 16, 2025.
Summary
- On May 16, 2025, Matthew Klein, a director of ClearPoint Neuro, Inc. (CLPT), settled 21,093 restricted stock units into shares of common stock.
- The restricted stock units were granted on May 16, 2024, and vested on the earlier of the first anniversary of the grant date or the day immediately preceding the Company's 2025 annual meeting of stockholders.
- Following the transaction, Klein directly owns 50,518 shares of ClearPoint Neuro common stock.
- A power of attorney is in place, authorizing Danilo D'Alessandro to act on behalf of Matthew B. Klein for SEC filings.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock transactions, indicating a neutral sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions and provides transparency to investors regarding the holdings and transactions of company insiders.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 1/8/2025 | Date of execution of Power of Attorney. |
| 05/16/2024 | Date the reporting person was granted 21,093 restricted stock units. |
| 05/16/2025 | Date of transaction: settlement of restricted stock units. |
| 05/19/2025 | Date of Form 4 signature. |
Keywords
ClearPoint Neuro, Director, Matthew Klein, Restricted Stock Units, Form 4, Beneficial Ownership, CLPT
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.